Observational studyHypertension research : official journal of the Japanese Society of Hypertension2026
Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes.
Observational study in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination therapy with a sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) is increasingly used to prevent cardiovascular events. Our previous study demonstrated the renal benefits of this combination therapy. Both drug classes exert pleiotropic effects on metabolic factors, such as obesity and hypertension; however, the impact of this combination therapy on blood pressure (BP) has not been fully evaluated. This post hoc analysis aimed to assess the effects of SGLT2i-GLP-1RA combination therapy on BP control in patients with type 2 diabetes (T2D). Among the 643 T2D patients enrolled in the RECAP study, 431 with baseline hypertension were analyzed (GLP-1RA-preceding group, n = 207; SGLT2i-preceding group, n = 224). The achievement rate of the target office BP ( < 130/80 mmHg) after the initiation of combination therapy was evaluated using multiple imputations. Changes in office and home BP were analyzed using generalized linear mixed models. The influence of preceding treatment was assessed using propensity score-based inverse probability weighting (PS-IPW). The achievement rate of the target BP increased from 25.4% after treatment to 33.3% after combination therapy (p = 0.003). Office BP decreased from 141.8/82.4 mmHg at baseline to 135.2/78.5 mmHg after treatment addition and 131.7/79.4 mmHg after combination therapy (all p < 0.001). The home systolic BP also significantly decreased (p = 0.03). PS-IPW analysis showed no significant differences in BP outcomes or target achievement rates according to the preceding treatment. Collectively, SGLT2i-GLP-1RA combination therapy significantly improved BP control, independent of the order in which the agents were initiated.
Indexed as
Identifiers
42243292What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.